Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

Amylyx Pharmaceuticals will present a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026, at 9:30 a.m. ET. A live webcast will be available on the company's investor website, with a 90-day replay. The announcement contains no new business or clinical developments; it is a standard investor-calendar notice.

•1mo ago

Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors

Tortugas Neuroscience, a private clinical-stage CNS biotech launched in April 2026, appointed Jim Frates to its Board of Directors and as Chair of its Audit Committee. Frates has served as CFO of Amylyx Pharmaceuticals (Nasdaq: AMLX) since 2021 and previously spent more than two decades as CFO of Alkermes plc (Nasdaq: ALKS), during which Alkermes grew past $1 billion in revenue and 2,000 employees. For filer ALKS the news is tangential: Frates left Alkermes years ago, and the appointment at an unrelated private company has no bearing on Alkermes' operations, financials, or governance.

•1mo ago

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

Amylyx Pharmaceuticals announced that management will present at the 24th Annual Morgan Stanley Global Healthcare Conference, with a fireside chat scheduled for Tuesday, September 15, 2026, at 12:20 p.m. ET. A live webcast will be accessible in the Events and Presentations section of the company's investor website, and a replay will remain available for 90 days following the event. Amylyx is currently focused on four investigational therapies across endocrine conditions and neurodegenerative diseases; the release contains no new clinical, regulatory, or financial information.

•1mo ago

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

Amylyx Pharmaceuticals announced that topline results from the Phase 3 LUCIDITY clinical trial of Avexitide in post-bariatric hypoglycemia will be released on August 18, 2026. Senior management will host a conference call and audio webcast at 8:00 a.m. ET to discuss the findings. The webcast will be archived and available for replay on the company's investor relations website for 90 days.

•2mo ago

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

Amylyx reported a Q2 net loss of $43.4 million, or $0.39 per share, compared to a loss of $41.4 million a year ago, with R&D expenses decreasing to $23.8 million and SG&A rising to $21.9 million driven by legal costs. The company confirmed the final patient visit in the Phase 3 LUCIDITY trial of avexitide, with topline data anticipated in late August or early September 2026. Cash position stood at $250.8 million at quarter-end, providing a runway into 2028.

•2mo ago

Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

Amylyx Pharmaceuticals announced it will report its second-quarter 2026 financial results on Thursday, August 6, 2026. Senior management is scheduled to host a conference call and audio webcast at 8:00 a.m. ET to discuss the results and provide corporate updates. The event will be accessible via telephone or live webcast, with a replay available on the company's investor relations website for 90 days.

•2mo ago

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

Amylyx Pharmaceuticals announced two poster presentations at the Endocrine Society’s ENDO 2026 meeting in Chicago, scheduled for June 14-15, 2026. The posters cover the burden of post-bariatric hypoglycemia (PBH) and participant-centric design considerations for the pivotal Phase 3 LUCIDITY trial of avexitide. Avexitide is a first-in-class GLP-1 receptor antagonist with Breakthrough Therapy Designation for PBH; the LUCIDITY trial involves 78 participants across 21 U.S. sites.

•4mo ago

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx reported a Q1 net loss of $41.3 million, or $0.37 per share, with cash, cash equivalents, and short-term investments totaling $279.8 million as of March 31, 2026. The company expects its current cash position to fund operations into 2028, covering the potential commercialization of avexitide, while R&D expenses increased to $27.6 million primarily due to clinical trial activity. Management confirmed enrollment is complete in the Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia, with topline data anticipated in Q3 2026 and a potential 2027 launch if approved.

•5mo ago

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals announced that management will participate in the Bank of America 2026 Health Care Conference on May 13 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10. Both events will feature fireside chats conducted in-person, with live webcasts available on the company's investor relations website. Replays of the presentations will be available for 90 days following the events.

•5mo ago

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Amylyx Pharmaceuticals announced it will report its first quarter 2026 financial results on Thursday, May 7, 2026. Senior management is scheduled to host a conference call and audio webcast at 8:00 a.m. ET to discuss the results and provide business updates. A replay of the webcast will be archived and accessible on the company's investor relations website for 90 days following the event.

•6mo ago